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In this issue of the Journal two review articles (one immunologic, one epidemiologic) draw
attention to the human gut microbiome and its potential importance in human health and the
development of allergic and autoimmune disease1, 2. This editorial will try to synthesize the
central messages of these reviews and outline the research directions in this emerging field. I
will first review the data on the human microbiome, discuss factors that might influence gut
bacterial colonization in humans, review the evidence that the microbiome is involved in
allergic disease, and finally, consider the role of vitamin D in this process.
The gut microbiome is overwhelming in its size and its metabolic and antigenic complexity.
There are 1014 bacteria in the gut, or 10 times more microbes in the human colon than there
are cells in the human body. These bacteria belong to over 1000 species and have 3.3
million genes, over 150 times more genes than our own genome3. Culture alone is
inadequate to identify the mostly anaerobic organisms of the gut, and bacterial sequencing
must be used, in conjunction with culture, to definitively speciate, and hence identify, all of
these organisms.
These bacteria interact with the host in a variety of ways. First, they interact with the gut-
associated lymphoid tissue (GALT), the largest immune organ in the human body, and by
their sheer size, they represent the major source of antigenic load to the human immune
system. Second, these bacteria function as a metabolically active force to digest and modify
the human diet. Third, our own genome interacts with, and helps determine, which bacteria
are important to us4, thus providing a degree of complex gene environment interaction
effect. One of the most striking examples of this later effect is that animal brain function and
behavior can be influenced by the presence or absence of these commensual bacteria during
development5.
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The human gut flora is, quantitatively, the earliest, most diverse, and hence most important,
postnatal source of microbial stimulation of the immune system in most species, including
man, and hence the most likely determinant of normal tolerization6. Experiments in rodents
suggest that bacterial gut colonization is essential for the development of oral tolerance and
normal postnatal maturation of immune responses,7 including generation and/or expansion
of T regulatory cells (Tregs) in peripheral tissues.8 Most of these “good bacteria” are
anaerobes that are among the earliest life forms on the planet, having an evolutionary age of
almost 6 billion years relative to our much more recent, 150,000 years. Dobzhansky has said
that “nothing in biology makes sense except in light of evolution” and our coevolution with
these anaerobic bacteria is critical to our understanding of how our immune system
functions9. Ultimately how tolerization occurs, and how the gut microbiome relates to the
skin and other microbiomes, such as the oral cavity, is currently unknown. However, Noverr
and Huffnagle have postulated that the gut microbiome actually is the sensor for immune
tolerance in the lung6 What does seem clear is that tolerization as an immune phenomenon is
dominated by the gut flora because of the size of the GALT and the sheer magnitude of the
gut microbiome antigenic mass. Initial colonizing bacteria can be a potent environment
stimulus to the host, inducing genes in the host gut epithelium, and hence influencing host
immune response. Thus good bacteria can potentially control, or prevent the growth of
pathogenic bacteria, in part via immune system development and metabolic processes and
by mechanisms as yet not understood.10.
The natural history of microbial colonization of the human gut and its relevance to disease is
in its infancy. Existing studies in this area are few because of the novelty of the technology,
high cost, and technical difficulty culturing anaerobes. Methodological issues such as small
sample size, short duration of follow-up11, missing data on potentially relevant variables,
and most importantly reliance on cultures alone, may miss relevant organisms, thus limiting
what we know.12 Multiple clinical and molecular factors are likely to determine gut
colonization in early fetal life: bacterial characteristics such as number, diversity, cell
surface antigens, the presence or absence of pili, host mucosal cell properties such as cell
surface receptors, and epidemiologic factors such as gestational age, mode of delivery,
exposure to maternal fecal flora, maternal diet, fetal antibiotic use, and type of infant
feeding, including probiotics.10, 12, 13
Of the multiple factors noted above, the maternal and fetal diet and pre and probiotics
deserve some greater attention. At a CIBA symposium meeting in 1996 I was the first to
suggest that dietary changes could be driving the allergy and autoimmune disease
epidemic14. Food serves as an important substrate for bacteria digesting plant
polysaccharides and hence producing short chain fatty acids and other nutrients for the
bacteria and hence amplifying their influence immunologically15. This prebiotic function
could potentially be exploited therapeutically if we knew which foods were promoting the
“good” bacteria. Probiotics are cultures of normal gut flora organisms administered orally to
influence immune function.16 Several studies, mostly with lactobacillus, have been
performed17 including two small clinical trials18–20 The problem is that these studies are
premature, since they beg the critical question of what are the relevant bacteria and their
specific antigens that drive the putative immunoprotective effects. The evidence that
lactobacilli are sufficient to do this is weak at best. Bacteroides fragilis would seem be a
better bet, but unlike the mouse, a single bacterium is unlikely to be sufficient to achieve
normal immune tolerization in the human.
Existing clinical studies performed in the presequencing era, suggest that the composition of
the gut flora appears to differ between atopic and non-atopic infants; giving some credence
to the hypothesis that reduced number and diversity of gut bacteria early in life lead to faulty
tolerization and the development of allergic and other autoimmune disease.12, 21–25 Ly and
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coworkers review much of this work in greater detail2. In a small pilot study, we found that
similar results to those studies cited above. We found that IL-10, an anti-inflammatory, T-
reg controlling cytokine modulated in part by vitamin D, was increased in the cord blood of
children whose mothers had a higher number of anaerobes in their gut. We went on to show
that greater diversity of the infant fecal flora was protective for atopic dermatitis occurrence
at 6 months of age.26 A recent review found that 14 of 17 studies in this area supported the
findings that gut bacteria influenced the development of allergic disease27. These cited
studies, including ours, are mostly of small sample size and, most importantly, lack robust,
state of the art, gut microbiome assessment with both anaerobic culture and sequencing to
maximally speciate the organisms. Finally, most studies do not adequately account for the
confounding variables noted above. Suffice it to say, as the Ly review notes, we have no
clear epidemiologic evidence as to the importance of specific bacterial species and whether
number or diversity, or both, are the determining factors with regard to allergic diseases
generally, or asthma specifically. This is in contrast to Crohn’s disease where specific
bacteria have been identified28.
How is vitamin D related to this process? We have previously reviewed in these pages the
potential role of vitamin D deficiency in the development of allergic and autoimmune
diseases and specifically their dramatic rise in prevalence in the last 50 years29. As we
noted, vitamin D has clear structural effects on lung and airway development in utero29. It is
worth recapitulating the immune portion of the argument here. Vitamin D is essential in the
development and function of both T-regulatory cells30, 31 and dendritic cells32, 33. It seems
quite likely that Vitamin D is an important modulator of the signaling traffic between gut
bacteria surface antigens via its effects on dendritic cells and the T-regs not just in humans,
but in organisms as evolutionarily well preserved as the fly.
Experimental evidence suggests that biologically active form of vitamin D (1,25
(OH)2Vitamin D3) influences the process by which immune cells acquire signaling
molecules that enable them to migrate to normal extra lymphoid tissue sites, as well as sites
of inflammation. The gastrointestinal mucosa, as the main body surface exposed to
environmental antigens (specifically gut bacteria), has well-described tissue-specific
adhesion and chemo attractant “homing” receptors.34 Vitamin D can block or down regulate
gut homing of both normal immune and inflammatory cells. For example, vitamin D
receptor (VDR) gene expression is required for Dendritic and T cells and other immune cells
to control inflammation in the IL-10 knockout mouse model.35 By up-regulating normal
immune function of T-regs, specifically through il10 and TGFB1, vitamin D can promote
normal tolerization. Conversely, reduced vitamin D, or reduced number and diversity of gut
bacteria, or both, will promote inflammation that may disrupt the mucosal barrier, and
promote food and other allergen sensitization or abnormal tolerization. Thus pathogenic and
commensal gut bacteria may play opposing roles in allergy development, and these roles
may be modulated by the VDR, other host genes, and by vitamin D itself. It is also possible
that independent of its immune effects, vitamin D has a direct effect on gut bacterial flora to
increase or decrease the number of specific species of bacteria or species diversity. These
complex effects are synthesized in figure 1. Given the current IOM report on vitamin D
dosage, it is worth considering what level of vitamin D would provide immunoprotection for
the development of allergic and autoimmune disease (IOM report). While this is currently
unknown, it would seem that higher doses than those currently recommended by the IOM
report for bone health will almost certainly be necessary. Further research is needed in this
area.
It is worth noting that the microbiome/vitamin D hypothesis to explain the origins of the
autoimmune disease epidemic fits the facts far better than the hygiene hypothesis29. The
hygiene hypothesis never could explain the rise in Th1 autoimmune disease, in addition to
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asthma and allergy, and the high rates of asthma, and allergy among the urban poor in the
US. Both phenomena are easily explained by vitamin D deficiency. The strong link between
the microbiome and vitamin D closes the loop by providing a plausible immunologic
substrate for vitamin D effects on normal tolerization. We have clear evidence for dramatic
changes in vitamin D levels over the 50 year period that has seen the dramatic increase in
autoimmune disease; what we don't know is what has happened to the gut microbiome
during that period. Current clinical trials in the US and Denmark will test whether giving
vitamin D to pregnant women will prevent asthma in their offspring (Vitamin D Antenatal
Asthma Reduction Trial, VDAART, U01 HL091528, ClinicalTrials.gov: NCT00856947)
although this is unlikely to be the whole story as this trial will not test the effect of postnatal
sufficiency on asthma risk. A funded ancillary study will allow an exploration of the relative
importance of vitamin D and the gut flora on disease risk.
Identification of the “good bacteria” in the human gut microbiome is of primary scientific
importance in understanding allergic diseases. This will not be a trivial exercise given the
size and diversity of the gut microbiome. If this task can be accomplished, then it is
conceivable that in the not too distant future we will prevent asthma, food allergies, atopic
dermatitis, allergic rhinitis, and other autoimmune diseases like Crohn’s disease, type 1
Diabetes Mellitus, and Multiple Sclerosis with a cocktail of anaerobic bacterial antigens,
dietary constituents, or the bacteria themselves (prebiotics and probiotics) in combination
with vitamin D, administered orally to both pregnant women and their offspring, but first we
need to find the protective bacterial species, identify their antigens, understand more clearly
how vitamin D modulates the signaling from gut bacteria to dendritic cells and to T-regs,
and what dose of vitamin D is necessary. This is an exciting time for asthma research, and
for autoimmune disease research generally, and the gut microbiome will be an important
extension of genomics to the environment. Elucidating its influence on the development of
allergic disease is going to certainly contribute to this excitement.
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Figure 1. Vitamin D May Determine How Gut Flora Interacts with the Immune System
Vitamin D may directly influence the number or diversity of the Gut microbiota. It does
influence dendritic cell antigen processing but how it does this with gut bacteria is unknown.
It controls immune trafficking between dendritic cells and T-reg cells. Finally, through IL10,
and TGFB1, it modulates T-ref function through all three effector arms of the adaptive
immune response TH1, TH2, and TH17.
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